Transillumination Device for Peripheral Intravenous Placement in Patients With Sickle Cell Disease (PERFID)
Transillumination Device for Peripheral Intravenous Placement in Patients With Sickle Cell Disease (PERFID)
The primary goal of this randomized, controlled, open-label study is to determine the
 efficacy of AccuveinV400 (a transillumination veins device) to facilitate peripheral
 intravenous (IVP) catheter placement during a vaso-oclusive crisis. The investigators
 hypothesized that the number of attempts to a successful placement of a peripheral IV, our
 primary outcome, would be shorter with the assistance of the Accuvein V400. It is also
 expected that AccuveinV400 will reduce the time of the procedure, the rate of failure, the
 technique-related pain.
Inclusion Criteria:

 -  Sickle cell patients (all genotypes)

 -  Patients hospitalized for uncomplicated vaso-occlusive crisis (CVO) in
 Internal/general Medicine department

 -  Patients requiring the placement or replacement of a peripheral intra-venous catheter
 in the Department of Internal/general Medicine

 -  Patients arrived in the internal/general medicine department of the hospital between
 9h and 18h and except weekends

 -  Signed informed consent.

 -  Affiliated to the French health care insurance.

 Exclusion Criteria:

 -  Signs of shock

 -  Acute chest Syndrome

 -  Central venous catheter already present

 -  Indication to have a central venous catheter from the ourset

 -  Patient who has already participated to the PERFID study during the current
 hospitalization

 -  Refusal of the patient's participation

 -  Pregnant or lactating woman

 -  Patient under guardianship or curatorship